Human MMP-2 Antibody

Detection of MMP-2 by Western Blot

Abolishment of TGF-beta 1-mediated matrix remodeling by p38 and JNK inhibitors in the primary cultured orbital fibroblasts from patients with Graves’ ophthalmopathy (GO). (A) Orbital fibroblasts from GO patients were preincubated with the p38 inhibitor SB202190 (20 μM) and the JNK inhibitor SP600125 (20 μM), respectively, for 1 h, followed by TGF-beta 1 (5 ng/mL) treatment for another 24 h. Then, the expression levels of TIMP-1, TIMP-3, MMP-2, and MMP-9 were analyzed by Western blots; (B) The relative intensities of TIMP-1, TIMP-3, MMP-2, and MMP-9 expression normalized to each GAPDH control and DMSO control without TGF-beta 1 treatment were defined as 1.0. Then, the other relative intensity (folds) was presented. By three independent Western blot experiments, together data from the same patient strain were averaged. Then, the means of different patient (GO1–GO4, n = 4) strains were averaged; (C) The enzyme activities of MMP-2/-9 from the cultured medium were determined. The representative histogram was plotted based on the mean values of relative fluorescence units from the primary cultured orbital fibroblasts from the four GO patients. Data were presented as means ± S.D. of the results from three independent experiments. * p < 0.05 and ** p < 0.01 vs. control without TGF-beta 1 treatment; # p < 0.05 and ## p < 0.01 vs. TGF-beta 1 treatment. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33799469), licensed under a CC-BY license. Not internally tested by R&D Systems.